Lisa E. Porter

1.8k total citations · 1 hit paper
10 papers, 1.5k citations indexed

About

Lisa E. Porter is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Lisa E. Porter has authored 10 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Molecular Biology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Lisa E. Porter's work include Diabetes Treatment and Management (6 papers), Metabolism, Diabetes, and Cancer (4 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). Lisa E. Porter is often cited by papers focused on Diabetes Treatment and Management (6 papers), Metabolism, Diabetes, and Cancer (4 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). Lisa E. Porter collaborates with scholars based in United States, United Kingdom and India. Lisa E. Porter's co-authors include Ken Wilhelm, Brandon Walsh, Martin I. Freed, Ping Yan, Leigh MacConell, Richard M. Bergenstal, Jaret Malloy, Carol Wysham, Mark Heise and Norman K. Hollenberg and has published in prestigious journals such as The Lancet, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

In The Last Decade

Lisa E. Porter

10 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

2010 510 citations Richard M. Bergenstal, Carol Wysham et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa E. Porter United States	8	1.1k	570	353	278	277	10	1.5k
Fady T. Botros United States	18	1.1k 1.0×	704 1.2×	358 1.0×	339 1.2×	266 1.0×	40	1.6k
Ambady Ramachandran India	6	1.5k 1.3×	572 1.0×	448 1.3×	255 0.9×	292 1.1×	9	1.6k
Ira Gantz United States	12	1.8k 1.6×	767 1.3×	694 2.0×	506 1.8×	246 0.9×	24	2.3k
P. Damsbo Denmark	18	722 0.6×	521 0.9×	343 1.0×	131 0.5×	155 0.6×	20	1.4k
Maria Gerasimova United States	9	974 0.9×	528 0.9×	600 1.7×	89 0.3×	154 0.6×	12	1.4k
Lin Ping United States	8	2.2k 2.0×	919 1.6×	739 2.1×	332 1.2×	420 1.5×	11	2.4k
Sabine Pinnetti Germany	17	1.5k 1.3×	797 1.4×	869 2.5×	114 0.4×	214 0.8×	22	1.6k
H.J. Woerle Germany	18	1.6k 1.4×	745 1.3×	701 2.0×	126 0.5×	259 0.9×	31	1.7k
Tsukasa Morii Japan	18	553 0.5×	359 0.6×	327 0.9×	94 0.3×	125 0.5×	29	1.3k
Akemi Katsurada United States	21	788 0.7×	294 0.5×	176 0.5×	910 3.3×	157 0.6×	36	1.4k

Countries citing papers authored by Lisa E. Porter

Since Specialization

Citations

This map shows the geographic impact of Lisa E. Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa E. Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa E. Porter more than expected).

Fields of papers citing papers by Lisa E. Porter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa E. Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa E. Porter. The network helps show where Lisa E. Porter may publish in the future.

Co-authorship network of co-authors of Lisa E. Porter

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa E. Porter. A scholar is included among the top collaborators of Lisa E. Porter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa E. Porter. Lisa E. Porter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Bergenstal, Richard M., Carol Wysham, Leigh MacConell, et al.. (2010). Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. The Lancet. 376(9739). 431–439. 510 indexed citations breakdown →

2.

Buse, John B., Daniel J. Drucker, Kristin Taylor, et al.. (2010). DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care. 33(6). 1255–1261. 282 indexed citations

3.

Bakris, George L., Luís M. Ruilope, Stephen McMorn, et al.. (2006). Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. Journal of Hypertension. 24(10). 2047–2055. 85 indexed citations

4.

Rosenstock, Julio, B. J. Goldstein, A Vinik, et al.. (2005). Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obesity and Metabolism. 8(1). 49–57. 52 indexed citations

5.

Smith, Stephen A., Lisa E. Porter, Nandita Biswas, & Martin I. Freed. (2004). Rosiglitazone, But Not Glyburide, Reduces Circulating Proinsulin and the Proinsulin:Insulin Ratio in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 89(12). 6048–6053. 47 indexed citations

6.

Bakris, George L., Giancarlo Viberti, Wayde M. Weston, et al.. (2003). Rosiglitazone reduces urinary albumin excretion in type II diabetes. Journal of Human Hypertension. 17(1). 7–12. 201 indexed citations

7.

Holman, Rury R., et al.. (2003). Levels of beta-cell dysfunction and insulin resistance differ between Europeans and North Americans with recently-diagnosed diabetes in the ADOPT study. Diabetologia. 46. 1 indexed citations

8.

Price, Deborah A., Lisa E. Porter, Michael Gordon, et al.. (1999). The Paradox of the Low-Renin State in Diabetic Nephropathy. Journal of the American Society of Nephrology. 10(11). 2382–2391. 224 indexed citations

9.

Porter, Lisa E. & Norman K. Hollenberg. (1998). Obesity, Salt Intake, and Renal Perfusion in Healthy Humans. Hypertension. 32(1). 144–148. 49 indexed citations

10.

Porter, Lisa E.. (1997). Obesity, salt intake, and renal perfusion in healthy humans. American Journal of Hypertension. 10(4). 18A–18A. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact